StockData

Incannex Healthcare vs Lisata Therapeutics

IXHL and LSTA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IXHL and LSTA compare

Incannex Healthcare is the larger company, worth 2.5 times as much as Lisata Therapeutics ($24.2M against $9.8M).

Incannex Healthcare scores higher on the StockData Score (7 against 6 for Lisata Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIXHLLSTA
Size and price
Market cap$24.2M$9.8M
Share price$1.93$1.09
Change, 1 year−82.0%−47.3%
Change, 5 years–−92.6%
Beta (5Y)2.26−1.65
Employees1221
StockData Score
Total score7 (better)6
Valuation score11
Growth score00
Performance score1 (better)0
Health score55
Dividend score00
Valuation
P/S–98.2×
P/B0.4× (better)1.2×
FCF yield−13.2% (better)−125%
Growth
Revenue growth (TTM)–−90.7%
Profitability
Operating margin–−16427%
Net margin–−14621%
FCF margin–−12323%
Return on equity−20.7% (better)−99.9%
Return on invested capital−1945%−1645% (better)
Financial health
Debt / equity0.000.00
Current ratio67.79 (better)3.69
Altman Z-score0.11 (better)−74.72
Piotroski F-score4 (better)1
Dividends and buybacks
Buyback yield−38.0%−6.0% (better)
Shareholder yield−38.0%−6.0% (better)
Ownership
Held by institutions3.6%12.1%
Held by insiders–11.6%
Short interest, % of float–0.43%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.